Carboplatin
Oral Cavity Squamous Cell Carcinoma
Explore 11 assets in Oral Cavity Squamous Cell Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Rapa Therapeutics LLC
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05144698CT.gov RAPA-201 Therapy of Solid Tumors | — | Recruiting | — | — | — |
NCT01249443CT.gov Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | — | Terminated | — | — | — |
NCT00004074CT.gov Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oral Cavity Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Rapa Therapeutics LLC | P1/2 | B · 57 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| Abiraterone | MacroGenics | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Enzalutamide | MacroGenics | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Pembrolizumab | Rapa Therapeutics LLC | P1/2 | CCC |
| Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 | Rapa Therapeutics LLC | P1/2 | CCC |
+14 more in the Oral Cavity Squamous Cell Carcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Oral Cavity Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-oral-cavity-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →